About the Study

For adults with cognitive impairment associated with symptoms of schizophrenia

The goal of this study is to evaluate the efficacy, safety, and tolerability of ALTO-101T (transdermal patches) versus placebo in normalizing EEG (electroencephalogram) cognitive processing markers and cognition itself. This study is sponsored by Alto Pharma.

Length of Study:  About 11 Weeks Total : 8 Visits

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 21-55 years old
• have been diagnosed with schizophrenia
• are currently taking medication for schizophrenia
• believe you are experiencing cognitive impairment from symptoms of schizophrenia.

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.